← brief for 2026-10-02 · Slowing decline

Association of SGLT2 inhibitors and GLP-1 receptor agonists with mortality and renal outcomes in patients with diabetes and chronic kidney disease: the diabetic nephropathy management and outcome (DINAMO) study

Article C Peer reviewed Observational

Key takeaways

This large study looked at real-world data from Israel. It found that people with diabetes and kidney disease who took SGLT2 inhibitors or GLP-1 drugs had lower rates of death and kidney failure. This is an observational study, so it shows a link, not proof of cause.

Who did this work

Keren Cohen‐Hagai · Tali Zitman‐Gal · Kalantar-Zadeh Kamyar · Yael Einbinder · Ela Giladi · Abid R. Assali · Ilan Rozenberg · David Pereg

Source

Article · OpenAlex, CKD works · 2026-10-01
https://doi.org/10.1186/s12933-026-03382-y